P-6313
Transplantation and Cellular Therapy | 2026
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis.
Wudhikarn K, Gowda L, Ye Q, Oloyede T, Martens M, Banerjee R, Devarakonda SS, Liu H, Herr MM, Young JH, Jain T, Dias A, 13. Nishihori T, Mirza AS, Ganguly S, Beitinjaneh AM, Aljurf M, Wirk B, Farhadfar N, Efebera YA, Perales MA, Ebens CL, Murthy HS, Hill JA, Dandoy CE, Hong S, Boghdadly ZE, 28. Akhtar OS, Auletta JJ, Huppler AR, Abid MB
PubMed
PMID: 42364732
CIBMTR Study #: IN23-01